Your browser doesn't support javascript.
loading
Blockade of glucagon signaling prevents or reverses diabetes onset only if residual ß-cells persist.
Damond, Nicolas; Thorel, Fabrizio; Moyers, Julie S; Charron, Maureen J; Vuguin, Patricia M; Powers, Alvin C; Herrera, Pedro L.
Affiliation
  • Damond N; Department of Genetic Medicine and Development of the Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • Thorel F; Institute of Genetics and Genomics in Geneva, University of Geneva, Geneva, Switzerland.
  • Moyers JS; Centre facultaire du diabète, University of Geneva, Geneva, Switzerland.
  • Charron MJ; Department of Genetic Medicine and Development of the Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • Vuguin PM; Institute of Genetics and Genomics in Geneva, University of Geneva, Geneva, Switzerland.
  • Powers AC; Centre facultaire du diabète, University of Geneva, Geneva, Switzerland.
  • Herrera PL; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, United States.
Elife ; 52016 04 19.
Article in En | MEDLINE | ID: mdl-27092792
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Gastrointestinal Agents / Glucagon / Signal Transduction / Insulin-Secreting Cells / Insulin Limits: Animals Language: En Journal: Elife Year: 2016 Document type: Article Affiliation country: Switzerland Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Gastrointestinal Agents / Glucagon / Signal Transduction / Insulin-Secreting Cells / Insulin Limits: Animals Language: En Journal: Elife Year: 2016 Document type: Article Affiliation country: Switzerland Country of publication: United kingdom